Decentralized and adaptive trial designs move from pilot to default in biotech development plans
Dr. Dereck Mush, MD, MBA
Massive Bio
Uses AI to match cancer patients with clinical trials globally, expanding access.
What they do
Massive Bio provides an artificial intelligence-driven platform that matches cancer patients to clinical trials. Pharmaceutical companies, contract research organizations, and oncology practices use this service to accelerate patient recruitment and connect individuals to novel, targeted cancer therapies regardless of geographic location.
The record
- Vertical
- Oncology
- Sub-segment
- Clinical trial matching
- Product type
- Service
- Stage
- Series B
- Headquarters
- New York, United States
- Region
- North America
- Founded
- 2014
- Total funding
- $23M raised
Notable investors: Revo Capital, SBA Group, Kiraco, DEG.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The EHR Dark Data Goldmine: Why Sentence-Level Provenance Is Pharma's New Real-World Evidence Moat
Dr. Dereck Mush, MD, MBA
Decentralized Clinical Trials Promised Faster Recruitment. The Evidence on Actual Performance Is In.
Dr. Dereck Mush, MD, MBA
How to Build Clinical Evidence on a Startup Budget Before You Need It
Dr. Dereck Mush, MD, MBA